Drug Investigation

, Volume 5, Issue 4, pp 229–237 | Cite as

A Multicentre Double-Blind Placebo-Controlled Study of the Effect of a Pancreatic Enzyme Formulation (Panzytrat® 25 000) on Impaired Lipid Digestion in Adults with Chronic Pancreatitis

  • J. C. Paris
Original Research Article


In this multicentre double-blind placebo-controlled trial, the efficacy and tolerability of Panzytrat® 25 000, a pancreatic enzyme formulation, were examined in 72 patients with chronic alcoholic pancreatitis and steatorrhoea of ⩽ 10g per 24 hours. Patients received either Panzytrat® 25 000 or placebo as 2 capsules 3 times daily for 7 days. Of 41 patients who were in strict compliance with the study protocol, 24 received Panzytrat® 25 000 and 17 received placebo. Panzytrat® 25 000 produced a 50% reduction in mean steatorrhoea and decreases in mean creatorrhoea and stool weight of about 40%. These parameters increased slightly in the placebo group. Treatment efficacy, calculated as relative changes from baseline (i.e. the difference between preand post-treatment values divided by the baseline value for each patient), showed that Panzytrat® 25 000 reduced steatorrhoea (−40.9%), creatorrhoea (−29.3%), and stool weight (31.9%) compared with respective increases of 7.2, 11.1 and 8.8% in the placebo group (p = 0.001).

In the 60 patients in whom there were no major protocol deviations, 32 received Panzytrat® 25 000 and 28 received placebo (12 patients were excluded because of protocol violation). Panzytrat® 25 000 reduced mean steatorrhoea (≈ −50%), creatorrhoea (≈ −40%) and mean stool weight (≈ −30%) compared with slight increases in these parameters in the placebo group. Treatment efficacy, calculated as relative changes from baseline in each patient, showed decreases in steatorrhoea, creatorrhoea and stool weight of 35.6, 26.9 and 23.9%, respectively, with Panzytrat® 25 000, compared with increases of 1.9, 7.5 and 5.2%, respectively, in the placebo group (p = 0.001, 0.001 and 0.01, respectively).

In both analyses, Panzytrat® 25 000 appeared to be more effective in patients who had not undergone prior surgery compared with those who had received surgery considered likely to hamper treatment; however, differences between these subgroups were not statistically significant. Global efficacy of Panzytrat® 25 000 was considered ‘good or excellent’ by approximately 80% of patients and clinicians. Panzytrat® 25 000 was well tolerated, with 97% of patients and clinicians considering the drug to have ‘good or excellent’ tolerability.


Lipase Chronic Pancreatitis Drug Invest Pancreatic Enzyme Strict Compliance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anonymous. Choosing and using a pancreatic enzyme supplement. Drug and Therapeutics Bulletin 30: 37-40, 1992Google Scholar
  2. Beverley DW, Kelleher J, MacDonald A, Littlewood JM, Robinson T, et al. Comparison of four pancreatic extracts in cystic fibrosis. Archives of Diseases of Childhood 62: 564–568, 1987CrossRefGoogle Scholar
  3. DiMagno EP. Patterns of human exocrine pancreatic secretion and fate of human pancreatic enzymes during aboral transit. In Lankisch (Ed.) Pacreatic enzymes in health and disease, pp. 1–10, Springer-Verlag, Berlin, Heidelberg, 1991aCrossRefGoogle Scholar
  4. DiMagno EP. Future aspects of enzyme replacement therapy. In Lankisch (Ed.) Pancreatic enzymes in health and disease, pp. 209–214, Springer-Verlag, Berlin, Heidelberg, 1991bCrossRefGoogle Scholar
  5. DiMagno EP, Clain JE. Chronic pancreatitis. In Go et al. (Eds) Exocrine pancreas: biology, pathobiology and disease, pp. 541–575, Raven Press, New York, 1986Google Scholar
  6. DiMagno EP, Go VLW, Summerskill WHJ. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. New England Journal of Medicine 288: 813–815, 1973PubMedCrossRefGoogle Scholar
  7. DiMagno EP, Malagelada J-R, Go VLW. Relationship between alcoholism and pancreatic insufficiency. Annals of the New York Academy of Sciences 252: 200–207, 1975PubMedCrossRefGoogle Scholar
  8. Gow R, Bradbear R, Francis P, Shepard R. Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: effectiveness of an enteric coated preparation with and without antacids and cimetidine. Lancet 2: 1071–1074, 1981PubMedCrossRefGoogle Scholar
  9. Halgreen H, Thorsgaard Pedersen N, Worning H. Symptomatic effect of pancreatic enzyme therapy in patients with chronic pancreatitis. Scandinavian Journal of Gastroenterology 21: 104–108, 1986PubMedCrossRefGoogle Scholar
  10. Jorgensen BB, Pedersen TN, Worning H. Monitoring the effect of substitution therapy in patients with exocrine pancreatic insufficiency. Scandinavian Journal of Gastroenterology 26: 321–326, 1991PubMedCrossRefGoogle Scholar
  11. Kolbel C, Layer P, Hotz J, Goebell H. Der einfluss eines säuregeschützten, mikroverkapselten Pankreatinpraparats auf die pankreatogene Steatorrho. Medizinische Klinik 81: 85–86, 1986PubMedGoogle Scholar
  12. Lankisch PG. Conservative treatment of chronic pancreatitis. Digestion 37 (Suppl. 1): 47–55, 1987PubMedCrossRefGoogle Scholar
  13. Lankisch PG. Differential treatment of exocrine pancreatic insufficiency in chronic pancreatitis. In Lankisch (Ed.) Pacreatic enzymes in health and disease, pp. 191–208, Springer-Verlag, Berlin, Heidelberg, 1991CrossRefGoogle Scholar
  14. Lankisch PG, Lembcke B, Krichhoff P, Creutzfeldt W. Therapy of pancreatogenic steatorrhoea: a comparison between two acid protected enzyme preparations. Digestive Diseases and Sciences 10: 1174, 1987Google Scholar
  15. Lankisch PG, Lembcke B, Kirchhoff S, Hilgers R, Creutzfeldt W. Therapie der pankreatogenen Steatorrhoe. Vergleich zweier sauregeschutzter Enzympraparate. Deutsche Medizinische Wochenschrift 113: 15–17, 1988PubMedCrossRefGoogle Scholar
  16. Layer P, Go VLW, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. American Journal of Physiology 251: 475–480, 1986Google Scholar
  17. Meyer JH, Elashoff J, Porter-Fink V, Dressman J, Amiden GL. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology 94: 1315–1325, 1988PubMedGoogle Scholar
  18. Morrow JD. Topics in clinical pharmacology: pancreatic enzyme replacement therapy. American Journal of the Medical Sciences 298: 357–359, 1989PubMedCrossRefGoogle Scholar
  19. Peschke GJ. Active components and galenic aspects of enzyme preparations. In Lankisch (Ed.) Pacreatic enzymes in health and disease, pp. 55–64, Springer-Verlag, Berlin, Heidelberg, 1991CrossRefGoogle Scholar
  20. Schneider MU, Knoll-Ruzicka ML, Domschke S, Heptner G, Domschke W. Pancreatic enzyme replacement therapy. Comparative effects of conventional and enteric-coated microspheric pancreatin and acid stable fungal enzyme preparations on steatorrhoea in chronic pancreatitis. Hepato-Gastroenterology 32: 97–102, 1985PubMedGoogle Scholar
  21. Spicak J, Kordac V, Votruba M, Spicka I, Zavoral M, et al. Pancreatic enzymes in the treatment of chronic pancreatitis: comparison of Prolipase® and Panzynorm Forte®. Advances in Therapy 9: 62–67, 1992Google Scholar
  22. Stanescu A, Mayer D, Malfertheiner P. Behandlung der exokrinen pankreasinsuffizienz. Testung eines Pankreatin-Praparats aus säuregeschützten Mikrotabletten. Munchener Medizinische Wochenschrift 132: 313–316, 1990Google Scholar
  23. Stead RJ, Skypala I, Hodson ME, Batten JC. Enteric coated microspneres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax 42: 533–537, 1987PubMedCrossRefGoogle Scholar
  24. Vantini I, Fioretta A, Caliari S, Benini L, Brentegani MT, et al. Effects of two pancreatic enzyme-containing enteric-coated microsphere preparations on steatorrhoea in chronic alcoholic pancreatitis. Current Therapeutic Research 48: 268–274, 1990Google Scholar
  25. Worning H. The effect of enzyme substitution in patients with pancreatic insufficiency. Scandinavian Journal of Gastroenterology 15: 529–533, 1980PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • J. C. Paris
    • 1
  1. 1.Centre Hospitalier RégionalLilleFrance

Personalised recommendations